Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation complement-targeted antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, claseprubart (DNTH103), is engineered with extended half-life and high selectivity for active C1s complement protein, enabling self-administered subcutaneous injections. A second candidate, DNTH212, is a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2023
Apr 2022
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
